BBI608
D8807005
Phase 2 small_molecule completed
Quick answer
BBI608 for Malignant Pleural Mesothelioma is a Phase 2 program (small_molecule) at Sumitomo Pharma (Suzhou) Co., with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sumitomo Pharma (Suzhou) Co.,
- Indication
- Malignant Pleural Mesothelioma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed